Investors
Events & Presentations
Financial & Filings
Stock Information
Investor FAQs
Contact Us
Newsroom
Areas of Focus
Cardiometabolic
Severe Hypertriglyceridemia
Dyslipidemia
Cardiovascular Disease
Obesity
Pulmonary
Inflammatory Pulmonary Diseases
Idiopathic Pulmonary Fibrosis
Pipeline
Science & Innovation
Partnerships
Publications
Clinical Trials
Patients & Caregivers
What is RNAi?
Patient Centricity & Advocacy
Patient Stories
FCS Patient Insights
Expanded Access Programs
About
Leadership Team
Corporate Governance
Careers
Job Openings
Investors
Events & Presentations
Financial & Filings
Stock Information
Investor FAQs
Contact Us
Newsroom
Publications
Home
/
Science & Innovation
/
Publications
Filter by
Year Published
2025
2024
2023
2022
2021
2020
2019
2018
2017
2015
2013
2012
2011
2010
2007
2006
2005
2004
2003
2002
Selections
Clear Filters
Effect of Targeting apoC-III with Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia
Read More
Preclinical and Clinical Pharmacokinetics of JNJ-75220795, an siRNA Therapeutic Targeting PNPLA3, for Metabolic Dysfunction-Associated Steatohepatitis
Read More
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
Read More
Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD
Read More
Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)
Read More
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
Read More
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
Read More
A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2a in Patients with Advanced Clear Cell Renal Cell Carcinoma
Read More
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia – The SHASTA-2 Randomized Clinical Trial
Read More
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
Read More
1
2
3
4
5
...
7
Next
